CLEC10A marks an MHC class II-high tumour myeloid state that lies in T-cell-rich neighbourhoods, and its survival association is seen in MYCN non-amplified neuroblastoma

CLEC10A-positive tumour myeloid cells in neuroblastoma are enriched for MHC class II and sit in T-cell-richer neighbourhoods, with survival association only in MYCN non-amplified disease (pooled HR 0.77).

• Why it matters: Marker-positive versus marker-negative comparisons can be distorted by technical artefacts, and it was unclear whether CLEC10A carries prognostic information in neuroblastoma or what tumour myeloid state it reflects.
• What they did: Across three neuroblastoma cohorts (920 tumours), CLEC10A and overall survival were tested using MYCN-stratified Cox models with random-effects meta-analysis and Knapp-Hartung sensitivity; in GSE147766 and Visium HD, CLEC10A-positive and negative cells/bins were matched and spatially compared.
• The result: After matching, MHC class II dominated differential expression (seen in monocytes and macrophages in 7 of 7 patients) and S100 alarmin programme was lower; CLEC10A-positive bins were linked to T-cell-richer neighbourhoods (pooled paired difference 0.051, 95% bootstrap interval 0.003 to 0.134).

AI summary of the abstract · may contain errors · not medical advice · read the paper.